344 related articles for article (PubMed ID: 11983261)
1. Development of a DNA-MVA/HIVA vaccine for Kenya.
Hanke T; McMichael AJ; Mwau M; Wee EG; Ceberej I; Patel S; Sutton J; Tomlinson M; Samuel RV
Vaccine; 2002 May; 20(15):1995-8. PubMed ID: 11983261
[TBL] [Abstract][Full Text] [Related]
2. A human immunodeficiency virus 1 (HIV-1) clade A vaccine in clinical trials: stimulation of HIV-specific T-cell responses by DNA and recombinant modified vaccinia virus Ankara (MVA) vaccines in humans.
Mwau M; Cebere I; Sutton J; Chikoti P; Winstone N; Wee EG; Beattie T; Chen YH; Dorrell L; McShane H; Schmidt C; Brooks M; Patel S; Roberts J; Conlon C; Rowland-Jones SL; Bwayo JJ; McMichael AJ; Hanke T
J Gen Virol; 2004 Apr; 85(Pt 4):911-919. PubMed ID: 15039533
[TBL] [Abstract][Full Text] [Related]
3. Induction of multifunctional human immunodeficiency virus type 1 (HIV-1)-specific T cells capable of proliferation in healthy subjects by using a prime-boost regimen of DNA- and modified vaccinia virus Ankara-vectored vaccines expressing HIV-1 Gag coupled to CD8+ T-cell epitopes.
Goonetilleke N; Moore S; Dally L; Winstone N; Cebere I; Mahmoud A; Pinheiro S; Gillespie G; Brown D; Loach V; Roberts J; Guimaraes-Walker A; Hayes P; Loughran K; Smith C; De Bont J; Verlinde C; Vooijs D; Schmidt C; Boaz M; Gilmour J; Fast P; Dorrell L; Hanke T; McMichael AJ
J Virol; 2006 May; 80(10):4717-28. PubMed ID: 16641265
[TBL] [Abstract][Full Text] [Related]
4. Phase I clinical trial safety of DNA- and modified virus Ankara-vectored human immunodeficiency virus type 1 (HIV-1) vaccines administered alone and in a prime-boost regime to healthy HIV-1-uninfected volunteers.
Cebere I; Dorrell L; McShane H; Simmons A; McCormack S; Schmidt C; Smith C; Brooks M; Roberts JE; Darwin SC; Fast PE; Conlon C; Rowland-Jones S; McMichael AJ; Hanke T
Vaccine; 2006 Jan; 24(4):417-25. PubMed ID: 16176847
[TBL] [Abstract][Full Text] [Related]
5. A DNA/MVA-based candidate human immunodeficiency virus vaccine for Kenya induces multi-specific T cell responses in rhesus macaques.
Wee EG; Patel S; McMichael AJ; Hanke T
J Gen Virol; 2002 Jan; 83(Pt 1):75-80. PubMed ID: 11752703
[TBL] [Abstract][Full Text] [Related]
6. Construction and immunogenicity in a prime-boost regimen of a Semliki Forest virus-vectored experimental HIV clade A vaccine.
Hanke T; Barnfield C; Wee EG; Ågren L; Samuel RV; Larke N; Liljeström P
J Gen Virol; 2003 Feb; 84(Pt 2):361-368. PubMed ID: 12560568
[TBL] [Abstract][Full Text] [Related]
7. HIV-1 gp120 and Modified Vaccinia Virus Ankara (MVA) gp140 Boost Immunogens Increase Immunogenicity of a DNA/MVA HIV-1 Vaccine.
Shen X; Basu R; Sawant S; Beaumont D; Kwa SF; LaBranche C; Seaton KE; Yates NL; Montefiori DC; Ferrari G; Wyatt LS; Moss B; Alam SM; Haynes BF; Tomaras GD; Robinson HL
J Virol; 2017 Dec; 91(24):. PubMed ID: 29021394
[TBL] [Abstract][Full Text] [Related]
8. Efficient CD8+ T cell response to the HIV-env V3 loop epitope from multiple virus isolates by a DNA prime/vaccinia virus boost (rWR and rMVA strains) immunization regime and enhancement by the cytokine IFN-gamma.
Gómez CE; Abaitua F; Rodríguez D; Esteban M
Virus Res; 2004 Sep; 105(1):11-22. PubMed ID: 15325077
[TBL] [Abstract][Full Text] [Related]
9. Human Immunodeficiency Virus C.1086 Envelope gp140 Protein Boosts following DNA/Modified Vaccinia Virus Ankara Vaccination Fail To Enhance Heterologous Anti-V1V2 Antibody Response and Protection against Clade C Simian-Human Immunodeficiency Virus Challenge.
Styles TM; Gangadhara S; Reddy PBJ; Hicks S; LaBranche CC; Montefiori DC; Derdeyn CA; Kozlowski PA; Velu V; Amara RR
J Virol; 2019 Oct; 93(20):. PubMed ID: 31341049
[TBL] [Abstract][Full Text] [Related]
10. Drug evaluation: DNA/MVA prime-boost HIV vaccine.
Kent S; De Rose R; Rollman E
Curr Opin Investig Drugs; 2007 Feb; 8(2):159-67. PubMed ID: 17328232
[TBL] [Abstract][Full Text] [Related]
11. Induction of long-lasting multi-specific CD8+ T cells by a four-component DNA-MVA/HIVA-RENTA candidate HIV-1 vaccine in rhesus macaques.
Im EJ; Nkolola JP; di Gleria K; McMichael AJ; Hanke T
Eur J Immunol; 2006 Oct; 36(10):2574-84. PubMed ID: 17013988
[TBL] [Abstract][Full Text] [Related]
12. Novel recombinant Mycobacterium bovis BCG, ovine atadenovirus, and modified vaccinia virus Ankara vaccines combine to induce robust human immunodeficiency virus-specific CD4 and CD8 T-cell responses in rhesus macaques.
Rosario M; Hopkins R; Fulkerson J; Borthwick N; Quigley MF; Joseph J; Douek DC; Greenaway HY; Venturi V; Gostick E; Price DA; Both GW; Sadoff JC; Hanke T
J Virol; 2010 Jun; 84(12):5898-908. PubMed ID: 20375158
[TBL] [Abstract][Full Text] [Related]
13. Multiprotein HIV type 1 clade B DNA/MVA vaccine: construction, safety, and immunogenicity in Macaques.
Smith JM; Amara RR; McClure HM; Patel M; Sharma S; Yi H; Chennareddi L; Herndon JG; Butera ST; Heneine W; Ellenberger DL; Parekh B; Earl PL; Wyatt LS; Moss B; Robinson HL
AIDS Res Hum Retroviruses; 2004 Jun; 20(6):654-65. PubMed ID: 15242543
[TBL] [Abstract][Full Text] [Related]
14. Improving recombinant MVA immune responses: potentiation of the immune responses to HIV-1 with MVA and DNA vectors expressing Env and the cytokines IL-12 and IFN-gamma.
Abaitua F; Rodríguez JR; Garzón A; Rodríguez D; Esteban M
Virus Res; 2006 Mar; 116(1-2):11-20. PubMed ID: 16214252
[TBL] [Abstract][Full Text] [Related]
15. Broad and potent immune responses to a low dose intradermal HIV-1 DNA boosted with HIV-1 recombinant MVA among healthy adults in Tanzania.
Bakari M; Aboud S; Nilsson C; Francis J; Buma D; Moshiro C; Aris EA; Lyamuya EF; Janabi M; Godoy-Ramirez K; Joachim A; Polonis VR; Bråve A; Earl P; Robb M; Marovich M; Wahren B; Pallangyo K; Biberfeld G; Mhalu F; Sandström E
Vaccine; 2011 Oct; 29(46):8417-28. PubMed ID: 21864626
[TBL] [Abstract][Full Text] [Related]
16. Heterologous prime-boost-boost immunisation of Chinese cynomolgus macaques using DNA and recombinant poxvirus vectors expressing HIV-1 virus-like particles.
Bridge SH; Sharpe SA; Dennis MJ; Dowall SD; Getty B; Anson DS; Skinner MA; Stewart JP; Blanchard TJ
Virol J; 2011 Sep; 8():429. PubMed ID: 21899739
[TBL] [Abstract][Full Text] [Related]
17. A multigene HIV type 1 subtype C modified vaccinia Ankara (MVA) vaccine efficiently boosts immune responses to a DNA vaccine in mice.
Shephard E; Burgers WA; Van Harmelen JH; Monroe JE; Greenhalgh T; Williamson C; Williamson AL
AIDS Res Hum Retroviruses; 2008 Feb; 24(2):207-17. PubMed ID: 18240963
[TBL] [Abstract][Full Text] [Related]
18. DNA Vaccine-Induced Long-Lasting Cytotoxic T Cells Targeting Conserved Elements of Human Immunodeficiency Virus Gag Are Boosted Upon DNA or Recombinant Modified Vaccinia Ankara Vaccination.
Hu X; Valentin A; Cai Y; Dayton F; Rosati M; Ramírez-Salazar EG; Kulkarni V; Broderick KE; Sardesai NY; Wyatt LS; Earl PL; Moss B; Mullins JI; Pavlakis GN; Felber BK
Hum Gene Ther; 2018 Sep; 29(9):1029-1043. PubMed ID: 29869530
[TBL] [Abstract][Full Text] [Related]
19. Immunisation with recombinant modified vaccinia virus Ankara expressing HIV-1 gag in HIV-1-infected subjects stimulates broad functional CD4+ T cell responses.
Ondondo BO; Yang H; Dong T; di Gleria K; Suttill A; Conlon C; Brown D; Williams P; Rowland-Jones SL; Hanke T; McMichael AJ; Dorrell L
Eur J Immunol; 2006 Oct; 36(10):2585-94. PubMed ID: 17013989
[TBL] [Abstract][Full Text] [Related]
20. Prime-Boost Immunizations with DNA, Modified Vaccinia Virus Ankara, and Protein-Based Vaccines Elicit Robust HIV-1 Tier 2 Neutralizing Antibodies against the CAP256 Superinfecting Virus.
van Diepen MT; Chapman R; Douglass N; Galant S; Moore PL; Margolin E; Ximba P; Morris L; Rybicki EP; Williamson AL
J Virol; 2019 Apr; 93(8):. PubMed ID: 30760570
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
